地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18327026838
传真:18771997407
邮箱:sales@amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

艾美捷科技代理Pel-Freez 品牌。
在20世纪50年代,为了响应生物医学研究人员对材料的大量需求,Pel-Freez公司扩展到动物生物制品领域,并从那时起一直为生物医学界服务。在过去的几十年里,Pel-Freez进一步扩大了其产品范围。Pel-Freez提供包括各种动物组织、提取物和血液制品以及关键的人类生物制品。这些产品广泛应用于体外诊断试剂盒开发、药物发现、疫苗评估、HLA分型等领域。
Pel-Freez产品包括:
(1)冻干组织粉:提供多种动物组织的冻干粉,便于储存和使用,适用于各种生物化学和分子生物学实验。
(2)血清产品:包括正常兔血清和其他物种的血清产品,如人血清、人血浆等,用于细胞培养和生物医学研究。
(3)血浆和血液补体:提供人血浆和血液补体产品,用于免疫学研究和补体系统的功能分析。
(4)组织和抗体:提供多种组织的提取物和特异性抗体,支持基础研究和诊断开发。
Pel-Freez拥有专有的分离技术,能够去除超过96%的背景LGG和LGM抗体,同时保持补充功能。此外,其所有产品都经过高度标准化的生产过程,确保质量稳定可靠。Pel-Freez在疫苗开发用途兔补体方面是行业领导者,其热销产品涵盖人补体、成年(幼)兔补体、豚鼠补体等各类。Pel-Freez的客户群体包括全球的科研机构、制药公司、生物技术公司和临床诊断实验室,以及疫苗研究与开发领域的专家。Pel-Freez通过ISO 9001认证,确保其产品的质量和一致性。此外,其工厂和农场也遵循严格的伦理和人道动物实践标准。
<艾美捷科技代理Essange Reagents品牌全系列产品
Essange Reagents的核心使命是开发与分销精密工程化试剂,专注于血型鉴定试剂及特定血浆蛋白产品的研发生产。这些试剂严格遵循ISO13485标准精心制备,适用于体外诊断(IVD)和科研专用(RUO),为研究人员与医疗从业者提供可靠、可重复的结果支撑,助力其精准达成科研目标。Essange Reagents的IgG亚类试剂及多数CD单克隆抗体(专用于诊断领域)均经过全面技术文献验证。
▎Essange Reagents产品线
● 血型血清学:Cellbind微柱凝集卡、抗血清、试剂红细胞、Cellbind卡专用Magister C24全自动系统;
● 免疫试剂:IgG亚类试剂、单核细胞活化检测试剂、ELISA产品以及其他生物制品。

▎Essange Reagents产品列表
| 品名 | 货号 | Product group | 规格 | Techique |
| PeliCluster Anti-Lactoferrin | M9160BBC | Cytokines Immune reagents | 5 mg | Flowcytometry |
| PeliCluster Anti-CD62P | M9048BBC | Cytokines Immune reagents | 5 mg | Flowcytometry |
| PeliCluster Anti-Granzyme B with azide | M9174ABD | Immune reagents | 10 mg | Flowcytometry |
| PeliCluster Anti-Granzyme B | M9174 | Immune reagents | 5 mg | Flowcytometry |
| Anti-Vedolizumab antibody | M9265 | Biologics | - | ELISA |
| Anti-Tocilizumab antibody | M9264 | Biologics | - | ELISA |
| Anti-Dupilumab antibody | M9263 | Biologics | - | ELISA |
| Anti-Guselkumab antibody | M9262 | Biologics | - | ELISA |
| Anti-Daratumumab antibody | M9261 | Biologics | - | ELISA |
| PeliKine Human IL-6 ELISA Rapid Set A | M2018 | MAT | - | - |
| PeliKine Human IL-6 ELISA Rapid Set B | M2019 | MAT | - | - |
| Cellbind P3-P | K7211 | Blood grouping reagents Column | 3x10 mL | Cellbind |
| PEG 4000 20% | K1159 | Blood grouping reagents Potentiator | 20 mL | PEG-IAT: spin tube |
| PeliLISS | K1110 | Blood grouping reagents Potentiator | 10 mL | LISS-IAT: spin tube |
| BSA 22% (bovine serum albumin) | K1106 | Blood grouping reagents Potentiator | 10 mL | BSA-IAT: spin tube |
| PeliClass human IgG subclass Plus control 2 | M1898 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass human IgG subclass Plus control 1 | M1897 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass human IgG subclass Plus calibrator set | M1896 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass sheep anti human IgG4 Plus | M1894 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass sheep anti human IgG3 Plus | M1893 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass sheep anti human IgG2 Plus | M1892 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass sheep anti human IgG1 Plus | M1891 | IgG subclasses IMMAGE | - | Nephelometry |
| PeliClass human IgG subclass Plus kit | M1895 | IgG subclasses IMMAGE | - | Nephelometry/turbidimetry |
| Magister Control Software | K7320S2 | Blood grouping reagents Instruments Software | 1 piece | Cellbind |
| Magister Analysis Software | K7320S1 | Blood grouping reagents Instruments Software | 1 piece | Cellbind |
| Magister C24 | K7320 | Blood grouping reagents Instruments | 1 piece | Cellbind |
| HPE buffer | M1940 | Immune reagents | 55 mL | - |
| human IL-6 antibodies for ELISA | M9316 | Cytokines Immune reagents | - | - |
| Streptavidin poly-HRP | M2032 | Immune reagents | 1 mL | - |
| Cellbind Incubator | K7314 | Blood grouping reagents Instruments | - | - |
| Cellbind Centrifuge (12 cards) | K7312 | Blood grouping reagents Instruments | - | - |
| Cellbind Dispenser | K7300 | Blood grouping reagents Instruments | - | - |
| Streptavidin poly-HRP | M2051 | Immune reagents | 0,1 mL | - |
| Erytrocytenserologie | K3010 | Blood grouping reagents Educational services | - | - |
| Immunohaematology | K3010EN | Blood grouping reagents Educational services | - | - |
| PeliControl | K1379 | Blood grouping reagents Control | 2x8 ml | - |
| Cellbind DILUENT | K7180 | Blood grouping reagents Column | 100 mL | Cellbind |
| Cellbind LISS | K7130 | Blood grouping reagents Column | 3x25 mL | Cellbind |
| MASPAT Indicator Red Cells | K1139 | Blood grouping reagents Platelet crossmatch | 10 mL | - |
| Cellbind LISS | K7110 | Blood grouping reagents Column | 100 mL | Cellbind |
| MASPAT kit | K1360 | Blood grouping reagents Platelet crossmatch | 96 tests | - |
| MAT Cell Set HS | M2017 | MAT | - | - |
| PeliStrip elution kit | K1398 | Blood grouping reagents Elution | 15 tests | PEG DAT/IAT; spin tube |
| MAT Cell Set | M2016 | MAT | - | - |
| Makropanel 16 | K1385 | Blood grouping reagents Cells | 16x3 mL | IAT: spin tube |
| Screening panel 123 | K1148 | Blood grouping reagents Cells | 3x10 mL | IAT: spin tube |
| Cellbind ID16 | K7230 | Blood grouping reagents Column | 16x3 mL | Cellbind |
| Cellbind P3 | K7210 | Blood grouping reagents Column | 3x10 mL | Cellbind |
| Cellbind P2 | K7200 | Blood grouping reagents Column | 2x10 mL | Cellbind |
| Cellbind B reagent red cells | K7242 | Blood grouping reagents Column | 10 mL | Cellbind |
| Pelikloon polyspecific anti-human serum | K1193 | Blood grouping reagents Coombs sera | 10 mL | (LISS or albumin)-IAT/DAT; spin tube |
| MabTrack ADA infliximab | M2960 | Biologics | - | ELISA |
| Pelikloon anti-C3d monoclonal | K1377 | Blood grouping reagents Coombs sera | 10 mL | DAT; spin tube |
| MabTrack ADA adalimumab | M2950 | Biologics | - | ELISA |
| Pelikloon enhanced control | K1152 | Blood grouping reagents Control | 10 mL | - |
| MabTrack level infliximab | M2920 | Biologics | - | ELISA |
| MabTrack level adalimumab | M2910 | Biologics | - | ELISA |
| Monospecific anti-human IgG (goat) | K1131 | Blood grouping reagents Coombs sera | 10 mL | (LISS or PEG)-IAT/DAT; spin tube |
| anti-H (lectin) saline method | K1327 | ABO Blood grouping reagents | 3 mL | Saline: spin tube |
| Cellbind A1 reagent red cells | K7240 | Blood grouping reagents Column | 10 mL | Cellbind |
| anti-A1 (lectin) saline method | K1328 | ABO Blood grouping reagents | 5 mL | Saline: spin tube, MTP |
| Pelikloon anti-D mix (IgG/IgM) monoclonal | K1157 | Blood grouping reagents Rhesus | 10 mL | Saline, Spin tube, IAT, MTP, Cellbind |
| Pelikloon control monoclonal | K1156 | Blood grouping reagents Control | 10 mL | - |
| anti-Wra AGT method | K1344 | Blood grouping reagents Rare | 3 mL | IAT: spin tube |
| anti-s AGT method | K1343 | Blood grouping reagents Rare | 3 mL | IAT, spin tube |
| anti-Fyb AGT method | K1337 | Blood grouping reagents Rare | 3 mL | IAT, spin tube |
| Pelikloon anti-k (IgM) monoclonal | K1310 | 2 mL | Saline, spin tube | |
| Anti-Fya (IgG) monoclonal AGT method | K1236 | Blood grouping reagents Rare | 3 mL | IAT, spin tube, Cellbind |
| Pelikloon anti-Leb (IgA) monoclonal | K1317 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-K (IgM) monoclonal | K1199 | Blood grouping reagents Rare | 5 mL | Saline, Spin tube, MTP, Cellbind |
| Pelikloon anti-Lea (IgM) monoclonal | K1306 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-P1 (IgM) monoclonal | K1305 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-D enhanced (IgM) monoclonal | K1151 | Blood grouping reagents Rhesus | 10 mL | Saline, Spin tube, MTP, Cellbind |
| Pelikloon anti-D (IgM) monoclonal | K1255 | Blood grouping reagents Rhesus | 10 mL | Saline, Spin tube, MTP, Cellbind |
| Pelikloon anti-S (IgM) monoclonal | K1304 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-N (IgG) monoclonal | K1313 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-M (IgG) monoclonal | K1302 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Cellbind Direct Type | K7012 | ABO Column | 48 | Cellbind |
| Pelikloon anti-Jkb (IgM) monoclonal | K1301 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-Jka (IgM) monoclonal | K1300 | Blood grouping reagents Rare | 2 mL | Saline, spin tube |
| Pelikloon anti-Cw (IgM) monoclonal | K1201 | Blood grouping reagents Rhesus | 2 mL | Saline, spin tube |
| Cellbind Screen | K7000 | Blood grouping reagents Column | 48 cards | Cellbind |
| Pelikloon anti-e (IgM) monoclonal | K1205 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-E (IgM) monoclonal | K1204 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-c (IgM) monoclonal | K1203 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-C (IgM) monoclonal | K1202 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-e (IgM) monoclonal | K1197 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-c (IgM) monoclonal | K1196 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-C (IgM) monoclonal | K1195 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-E (IgM) monoclonal | K1191 | Blood grouping reagents Rhesus | 5 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-A,B (IgM) monoclonal | K1190 | ABO Blood grouping reagents | 3x10 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-B (IgM) monoclonal | K1189 | ABO Blood grouping reagents | 3x10 mL | Saline, spin tube, MTP, Cellbind |
| Pelikloon anti-A (IgM) monoclonal | K1188 | ABO Blood grouping reagents | 3x10 mL | Saline, spin tube, MTP, Cellbind |

艾美捷科技代理Lifecore品牌。
Lifecore生产透明质酸纳已逾40年,采用领先的微生物发酵和纯化工艺。产品包括:
(1)研究用标准产品
所有研究用途的NaHy均来自GMP批次,平均分子量为5kDa-1.8kDa。
(2)药物递送用水凝胶
Corgel®BioHydrogel产品具有生物相容性,可以定制用于各种医疗应用。
(3)GMP生产
让我们帮助您定制NaHy标签或进行化学修饰,使您达到GMP标准。
< " data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Lifecore品牌"> 艾美捷科技代理Lifecore品牌
艾美捷科技代理Ambinter品牌。
Ambinter隶属于Greenpharma品牌,是重要的药物发现专用化合物供应商。Ambinter拥有超过25年的合成经验,其数据库包含超过4600万种用于高通量筛选的化合物、构建模块以及各种片段和天然产物。Ambinter提供具有高度生物活性的复杂和稀有化学品。在Greenpharma的支持下,Ambinter还提供包括定制合成、化学信息学和分子建模、分析化学、研发项目管理在内的服务项目。
< " data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Ambinter品牌"> 艾美捷科技代理Ambinter品牌
艾美捷科技代理Nanoanalytics品牌全系列产品
nanoAnalytics GmbH创立于1999年,是一家专业从事表面、界面和微观分析领域材料表征的公司,公司的主要产品包括全自动细胞跨膜电阻测量仪(CellZscope)以及cellQART耗材产品。该公司致力于为药物研发、毒理学、基础细胞生物学以及屏障功能研究提供强大的实时、无标记分析工具,以满足科研和工业界对体外细胞屏障模型功能定量评估日益增长的高标准需求。此外,NanoAnalytics公司还提供材料表征服务,运用尖端测量设备,实现微米至纳米量级的材料表面与界面分析。

▍cellZscope产品线
cellZscope®系列是专为非侵入式、自动化测量细胞层跨上皮电阻(TEER)和细胞层电容(Ccl)而设计的先进仪器系统。这些系统能够在模拟体内环境的生理条件下,对生长在多孔膜上的细胞层进行长期、连续且高度自动化的阻抗监测。其技术核心在于利用精密的阻抗分析技术,在尽可能不干扰细胞自然状态的情况下,获取反映细胞层完整性和功能的关键电生理参数。其具有以下特点:
● 提供精确的阻抗读数,兼容广泛使用的标准细胞培养耗材;
● 通过计算机软件实现便捷的数据记录、分析和实验控制;
● 不干扰细胞正常生长环境---测量的数值更加真实;
● 测量采用更宽的频率范围---拟合的数据更加精确;
● 构建的数理模型更加细致---电生理参数更加丰富。
| cZs E | cZs + | cZs 2 | cZs 3 | |
| Output parameters | TEER | TEER, Ccl | TEER, Ccl | TEER, Ccl |
| Number of wells | 6 | 24 | 24 | 24 (96§) |
| Supported insert sizes | 6-/12-/24-well | 6-/12-/24-well | 6-/12-/24-well | 6-/12-/24-well |
| Different insert sizes combinable | ✔ | ✔ | ✔ | ✔ |
| Works with standard cell culture inserts | ✔ | ✔ | ✔ | ✔ |
| Wells / Electrodes autoclavable | ✔ | ✔ | ✔ | ✔ |
| Measuring interval adjustable | ✔ | ✔ | ✔ | |
| High-speed measurement | ✔ | ✔ | ||
| Docking Station | ✔ | ✔ | ||
| Up to 4 Cell Modules per Controller | ✔ |
▍cellQART产品线
cellQART®是nanoAnalytics公司推出的一套专为配合其核心产品cellZscope®系统使用而设计的高品质、即用型耗材系统。cellQART®提供了多种规格的培养插板(Inserts),兼容标准的多孔板格式,其多孔膜材质(如 PET)和孔径大小经过优化,以满足不同类型细胞培养和精确阻抗测量的需求。
| 分类 | 货号 | Membrane Optics | Pore Size | Pore Density |
| 24-Well Inserts | 932 04 02 | translucent | 0.4 µm | 1×108 /cm2 |
| 24-Well Inserts | 932 04 12 | clear | 0.4 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 02 | translucent | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 12 | clear | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 30 02 | translucent | 3.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 30 12 | clear | 3.0 µm | 0.6×106 /cm2 |
| 24-Well Inserts | 932 50 02 | translucent | 5.0 µm | 0.6×106 /cm2 |
| 24-Well Inserts | 932 50 12 | clear | 5.0 µm | 0.6×106 /cm2 |
| 24-Well Inserts | 932 80 02 | translucent | 8.0 µm | 0.2×106 /cm2 |
| 24-Well Inserts | 932 80 12 | clear | 8.0 µm | 0.1×106 /cm2 |
| 24-Well Inserts | 932 04 04 | translucent | 0.4 µm | 1×108 /cm2 |
| 24-Well Inserts | 932 04 14 | clear | 0.4 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 04 | translucent | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 14 | clear | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 04 06 | translucent | 0.4 µm | 1×108 /cm2 |
| 24-Well Inserts | 932 04 16 | clear | 0.4 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 06 | translucent | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 10 16 | clear | 1.0 µm | 2×106 /cm2 |
| 24-Well Inserts | 932 00 02 | - | - | - |
| 12-Well Inserts | 931 04 02 | translucent | 0.4 µm | 1×108 /cm2 |
| 12-Well Inserts | 931 04 12 | clear | 0.4 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 10 02 | translucent | 1.0 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 10 12 | clear | 1.0 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 30 02 | translucent | 3.0 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 30 12 | clear | 3.0 µm | 0.6×106 /cm2 |
| 12-Well Inserts | 931 50 02 | translucent | 5.0 µm | 0.6×106 /cm2 |
| 12-Well Inserts | 931 50 12 | clear | 5.0 µm | 0.6×106 /cm2 |
| 12-Well Inserts | 931 80 02 | translucent | 8.0 µm | 0.2×106 /cm2 |
| 12-Well Inserts | 931 80 12 | clear | 8.0 µm | 0.1×106 /cm2 |
| 12-Well Inserts | 931 04 04 | translucent | 0.4 µm | 1×108 /cm2 |
| 12-Well Inserts | 931 04 14 | clear | 0.4 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 10 04 | translucent | 1.0 µm | 2×106 /cm2 |
| 12-Well Inserts | 931 10 14 | clear | 1.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 04 02 | translucent | 0.4 µm | 1×108 /cm2 |
| 6-Well Inserts | 930 04 12 | clear | 0.4 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 10 02 | translucent | 1.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 10 12 | clear | 1.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 30 02 | translucent | 3.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 30 12 | clear | 3.0 µm | 0.6×106 /cm2 |
| 6-Well Inserts | 930 50 02 | translucent | 5.0 µm | 0.6×106 /cm2 |
| 6-Well Inserts | 930 50 12 | clear | 5.0 µm | 0.6×106 /cm2 |
| 6-Well Inserts | 930 80 02 | translucent | 8.0 µm | 0.2×106 /cm2 |
| 6-Well Inserts | 930 80 12 | clear | 8.0 µm | 0.1×106 /cm2 |
| 6-Well Inserts | 930 04 04 | translucent | 0.4 µm | 1×108 /cm2 |
| 6-Well Inserts | 930 04 14 | clear | 0.4 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 10 04 | translucent | 1.0 µm | 2×106 /cm2 |
| 6-Well Inserts | 930 10 14 | clear | 1.0 µm | 2×106 /cm2 |

艾美捷科技代理Peptides.de品牌全系列产品
Peptides.de是一家专注于高质量肽产品生产的的德国企业。公司创立于2001年,总部位于德国赫尼希斯多夫。从单一肽到百万级肽库,从线性链到环状结构,从短肽到超长序列,从粗品到高纯精肽,从修饰化到标记化,从天然氨基酸到非天然变体,Peptides.de提供全维度肽与肽模拟物解决方案,覆盖新抗原筛选、过继性免疫治疗、T细胞刺激实验、表位作图、ELISpot检测、药物发现及芯片技术等核心领域。
Peptides.de公司不仅生产肽,还自主开发用于肽合成的核心设备——肽合成机器人。凭借其专利技术超声肽合成平台 (USPS®),团队能够在短时间高效生产数百种肽,并精准实现客户所需的各种修饰。

▍ReVacc Scientific公司产品
Peptides.de核心业务涵盖:目录肽现货供应、专属肽链定制合成、个性化肽池构建、高通量肽库开发、肽芯片制备服务、功能型修饰肽生产以及精密预分装服务。

▍Peptides.de部分产品列表
| 品名 | 货号 | 规格 |
| ADV hexon (HLA-B*35:01) | EP07882_1 | 1 mg;5 mg |
| ADV hexon 114 -124 (HLA-B*07:02) | EP07881_1 | 1 mg;5 mg |
| ADV hexon 37-45 (HLA-A*24:02) | EP07880_1 | 1 mg;5 mg |
| ADV hexon 886-894 (HLA-A*01:01) | EP10774_1 | 1 mg;5 mg |
| ADV Hexon 917-925 (HLA-A*02:01) | EP07914_1 | 1 mg;5 mg |
| BKV VP1 108-116 (HLA-A*02:01) | EP11456_1 | 1 mg;5 mg |
| BRLF1 109-117 (HLA-A*02:01) | EP11139_1 | 1 mg;5 mg |
| Chlamydia trachomatis MOMP 258-266 (HLA-A*02:01) | EP11114_1 | 1 mg;5 mg |
| EBNA 3a (596-604) | EP10789_1 | 1 mg;5 mg |
| EBNA-1 Protein (562-570) | EP04510_1 | 1 mg;5 mg |
| EBV BALF-4 276-284 (HLA-A*02:01) | EP11237_1 | 1 mg;5 mg |
| EBV BMLF-1 280-288 (HLA-A*02:01) | EP07604_1 | 1 mg;5 mg |
| EBV BMRF1 116-128 (HLA-B*07:02) | EP11138_1 | 1 mg;5 mg |
| EBV BMRF1 208-216 (HLA-A*02:01) | EP11127_1 | 1 mg;5 mg |
| EBV BRLF-1 148-156 (HLA-A*03:01) | EP11482_1 | 1 mg;5 mg |
| EBV BRLF1 101-109 (HLA-A*29:02) | EP11142_1 | 1 mg;5 mg |
| EBV BRLF1 134-142 (HLA-A*11:01) | EP11140_1 | 1 mg;5 mg |
| EBV BRLF1 28-37 (HLA-A*24:02) | EP11141_1 | 1 mg;5 mg |
| EBV BZLF-1 190-197 (HLA-B*08:01) | EP07899_1 | 1 mg;5 mg |
| EBV BZLF-1 54-64 (HLA-B*35:01) | EP11143_1 | 1 mg;5 mg |
| EBV BZLF-1 54-64 mutant (HLA-B*35:01) | EP11144_1 | 1 mg;5 mg |
| EBV BZLF1 44-52 (HLA-B*07:02) | EP11214_1 | 1 mg;5 mg |
| EBV EBNA 3A 246-253 (HLA-A*24:02) | EP11147_1 | 1 mg;5 mg |
| EBV EBNA 3B 399-408 (HLA-A*11:01) | EP11150_1 | 1 mg;5 mg |
<艾美捷科技代理Vectorbiolabs品牌全系列产品
Vector Biolabs是一家专注于提供高质量AAV(腺相关病毒)和腺病毒产品的生物科技公司,总部位于宾夕法尼亚州费城。Vector Biolabs公司提供包括定制病毒载体生产、载体设计、克隆、扩增、包装、纯化和滴度测定在内的服务,并且拥有一个包含超过90,000种针对人类、小鼠和大鼠基因组定制的AAV产品目录,服务于包括生物制药公司和研究机构在内的全球客户。此外,Vector Biolabs 为研究界提供与基因表达、基因编辑和基因沉默相关的服务。

▍Vectorbiolabs公司的产品与服务
● AAV定制生产:根据客户需求,定制生产AAV载体,以满足特定的研究或治疗需求。
● AAV控制产品:提供一系列用于AAV基因治疗的控制产品,确保实验的准确性和可靠性。
● 腺病毒建设与扩增:提供腺病毒的构建和扩增服务,支持客户的病毒载体研究。
● shRNA筛选/验证与产品目录:提供shRNA筛选和验证服务,以及相关的产品目录,帮助客户进行基因沉默研究。
使用AAV进行基因治疗的好处:
①低免疫反应:AAV载体引发免疫反应的可能性较低,适合敏感应用。
②稳定的基因递送:提供非整合基因递送,降低诱变风险。
③可扩展的生产:确保从小规模到大规模的研究和临床试验的可靠供应。
④广泛的治疗应用:多功能性使其成为靶向大脑、肝脏和视网膜等器官的理想选择。
| 特性 | AAV | 腺病毒 (Adenovirus) |
| 基因表达 | 长期、稳定表达 | 快速、瞬时表达 |
| 免疫原性 | 低 | 高 |
| 装载容量 | ~4.7 kb | ~8 kb - 38 kb (大得多) |
| 趋向性/靶向能力 | 高 - 可通过不同衣壳定制 | 广泛,可靶向多种组织 |
| 最佳应用场景 | 体内研究,长期表达 | 体外 & 体内研究,癌症 & 疫苗研究 |
▍Vectorbiolabs部分产品列表
| 品名 | 货号 | AAV Serotype | AAV ITR | Promoter | Reporter | Storage Buffer | Titer | Viral Backbone | Volume (µL) |
| AAV1-LacZ | 7001 | AAV1 | AAV2 | CMV (ubiquitous) | LacZ | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV1-GFP | 7002 | AAV1 | AAV2 | CMV (ubiquitous) | eGFP | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV2-LacZ | 7003 | AAV2 | AAV2 | CMV (ubiquitous) | LacZ | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV2-GFP | 7004 | AAV2 | AAV2 | CMV (ubiquitous) | eGFP | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV5-LacZ | 7005 | AAV5 | AAV2 | CMV (ubiquitous) | LacZ | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV5-GFP | 7006 | AAV5 | AAV2 | CMV (ubiquitous) | eGFP | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV9-GFP | 7007 | AAV9 | AAV2 | CMV (ubiquitous) | eGFP | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV6-GFP | 7008 | AAV6 | AAV2 | CMV (ubiquitous) | eGFP | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV1-Cre | 7010 | AAV1 | AAV2 | CMV (ubiquitous) | - | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV2-Cre | 7011 | AAV2 | AAV2 | CMV (ubiquitous) | - | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV5-Cre | 7012 | AAV5 | AAV2 | CMV (ubiquitous) | - | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |
| AAV6-Cre | 7013 | AAV6 | AAV2 | CMV (ubiquitous) | - | PBS/5% Glycerol | 1x10^13 GC/ml | Recombinant AAV | 20 |

Cellular Dynamics公司可以大规模从干细胞诱导分化生产人类细胞,用于基础研究,药物发现和再生医学应用。CDI提供了几种末分化的细胞种类作为目录产品:iCell心肌细胞,iCell神经元,iCell内皮细胞和iCell肝细胞。 CDI的MyCell®产品组合能够为客户提供的供体样品进行重编程,基因编辑和分化。该公司还有几种来源于多能干细胞的原型产品,包括iCell心脏祖细胞,iCell造血祖细胞,iCell星形胶质细胞和iCell骨骼成肌细胞等。
Fujifilm, once a Company whose core business was photographic film, has diversified and strengthened its portfolio based on developing or acquiring proprietary technologies as well as a deeply held corporate philosophy of enhancing the quality of human lives worldwide. One key area of focus for the Company is Healthcare, and Fujifilm acquired Cellular Dynamics International in May 2015, renamed it to FUJIFILM Cellular Dynamics, Inc.(FCDI) in 2018 to drive innovation in this business area. We see great potential in FCDI as a key component in our mission to be the global leader in regenerative medicine and drug discovery through cutting-edge science and technology.
To date FCDI has already achieved leadership in the induced pluripotent stem cell (iPSC) field as one of the only companies in the world to industrially manufacture human cells derived from iPSCs with high quality, purity, and reproducibility and in virtually unlimited quantities. Not only have we achieved this across multiple healthy and diseased donors for the research market but also, we have begun to manufacture human cells under cGMP conditions – a requirement as these human cellular products move from a tool used in drug discovery into a therapy used in regenerative medicine applications.
Cellular Dynamics公司的主要产品包括:
iCell Cardiomyocytes
iCell Cardiac Progenitor Cells
iCell Neurons
iCell Astrocytes
iCell DopaNeurons
iCell Hepatocytes 2.0
iCell Hepatoblasts
iCell Skeletal Myoblasts
iCell Endothelial Cells
iCell Hematopoietic Progenitor Cells
iCell Macrophages
" data-original="http://fugene.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Cellular Dynamics"> Cellular Dynamics
艾美捷科技代理ReVacc Scientific品牌
ReVacc Scientific为科学发现、临床诊断和疾病治疗提供可靠的病毒学和免疫学产品和服务。
▍ReVacc Scientific公司产品
● 假病毒:带有报告基因(如荧光素酶)的假病毒,为样本高通量筛选提供了高效的解决方案。基于多种技术平台,ReVacc Scientific生产针对冠状病毒、丝状病毒或高致病性禽流感病毒的假病毒。
● 重组蛋白:公司专注于生产带有关键中和表位的蛋白质,这些蛋白质应用在疫苗、诊断和治疗三大重要领域。核心优势有:使用真核表达系统(哺乳/昆虫细胞)确保获得正确的翻译后修饰;生产的蛋白质能正确组装成其天然的多聚体状态(如二聚体、三聚体)。
● 单克隆抗体:大多数抗体具有中和活性,具有阻断病原体感染细胞的能力。
● 检测试剂盒:用于检测人、小鼠或兽医动物样本中的 IgG 或抗原水平,操作简便。
● 克隆工具:一步法高效组装;一分钟高效转化。

▍ReVacc Scientific公司服务
● 样本中和抗体效价评估:在符合生物安全要求的前提下,为您测定样本的中和活性;
● 定制化蛋白生产:根据需求生产携带特定突变的定制化蛋白;
● 定制化假病毒构建:根据需求生产携带特定突变的定制化假型病毒。
● 诊断试剂盒定制开发:根据需求开发定制试剂盒
● 定制化抗体发现:开发了多色表位特异性单细胞分选技术 (MESCS®),并结合重组单克隆抗体技术,从不同物种样本中发掘有价值的抗体。
● 抗体工程化改造:抗体人源化、抗体标记、抗体核苷酸序列测定、抗体同种型转换抗体格式转换以及抗体种属转换。
● 流式细胞分选服务:用于分选具有特定光散射和荧光特性的细胞群。
▍ReVacc Scientific部分产品列表
| 分类 | 品名 | 货号 | 规格 |
| Pseudovirus Reporter | VSV-Pseudovirus_SARS-CoV-2 WT (Wuhan Strain) Spike with luciferase reporter | P14N41 | 200 μl;1000 μl |
| Pseudovirus Reporter | Pseudovirus_RSV Fusion with Luciferase Reporter (A2 strain) | P11A48 | 200 μl;1000 μl |
| Pseudovirus Reporter | Lenti-Pseudovirus_SARS-CoV-2 (Wuhan Strain) Spike with luciferase reporter | O21F29 | 1.1ml;5.5ml |
| Pseudovirus Reporter | VSV-Pseudovirus_MERS-CoV Spike with luciferase reporter | T53L53 | 200 μl;1000 μl |
| Pseudovirus Reporter | VSV-Pseudovirus_SARS-CoV (2003 strain) Spike with luciferase reporter | V44X39 | 200 μl;1000 μl |
| Monoclonal Antibody | Anti-Dengue E Domain III Monoclonal Neutralizing Antibody | K34Q76 | 100 μg;500 μg |
| Monoclonal Antibody | Anti-Ebola Broad Neutralizing Antibody | P5N48 | 100 μg;500 μg |
| Monoclonal Antibody | Anti-HCV E2 Neutralizing Monoclonal Antibody | X81H49 | 100 μg;500 μg |
| Monoclonal Antibody | Anti-Herpes Simplex Virus gD Antibody | Y48B93 | 100 μg;500 μg |
| Monoclonal Antibody | Recombinant Human Anti-hMPV Fusion IgM Antibody | R7V27 | 20 μg;100 μg |
| Monoclonal Antibody | Recombinant Human Anti-hMPV Fusion IgA Antibody | A89X2 | 20 μg;100 μg |
| Recombinant Protein | Dengue virus 1 E protein | R22F8 | 100 μg;500 μg |
| Recombinant Protein | Ebola Sudan GP protein | B78A28 | 100 μg;500 μg |
| Recombinant Protein | Ebola Zaire Makona GP protein | P54P89 | 100 μg;500 μg |
| Recombinant Protein | Herpes simplex virus (HSV) gD protein (Type 1) | L61Q82 | 100 μg;500 μg |
| Recombinant Protein | HIV-1 Trimeric GP140 protein-clade B, YU2 strain | W44H24 | 100 μg;500 μg |
| Test kit | Human Kallikrein 3/PSA Quantitative ELISA (Ultra-sensitive) | S64N86 | 96-well |
| Test kit | Human Anti-Cytomegalovirus gB Protein Antibody IgG Titer Serologic Assay Kit | W19V42 | 96-well |
| Test kit | Human Anti-Dengue Antibody IgG Titer Serologic Assay Kit (E) | P76A64 | 96-well |
| Test kit | Human Anti-Ebola Antibody IgG Titer Serologic Assay Kit (Trimeric GP) | P78G86 | 96-well |
| Test kit | Human Anti-HIV-1 Antibody IgG Titer Serologic Assay Kit (Trimeric GP140) | R29T18 | 96-well |
| Cloning | Seamless Assembly Master Mix (2X) | Q72R56 | 50μl; 250μl;1ml |
| Cloning | One-Minute Competent Cells (Stbl2 similar) | L86Z19 | 8 x 50 μl; 96 x 50 ul |
| Cloning | One-Minute Competent Cells (DH5 Alpha) | L2A1 | 8 x 50 μl; 96 x 50 ul |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18771997407
传真:17754422825
邮箱:sales@amyjet.com
0.1838